← All investors

Boxer Capital
36 portfolio companies · 2 on the map · $360.9M raised · 2 cities
Portfolio map
2 Boxer Capital portfolio companies on the map.
Portfolio companies

Milestone Pharmaceuticals
Montreal
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Biotechnology Research$360.9MEst. 2007
SpringWorks Therapeutics
Stamford
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Biotechnology ResearchPublicEst. 2017
More portfolio companies
32 more Boxer Capital investments we track beyond the map — 36 tracked in total.
Ajax TherapeuticsCambridge · Series C
enGeneVancouver · Post-IPO Equity
Nuvation BioNew York · Post-IPO Equity
Biomea FusionRedwood City · Series A
Gossamer BioSan Diego · Post-IPO Equity
Tyra BiosciencesCarlsbad · Post-IPO Equity
Halda TherapeuticsNew Haven · Series B
Protara TherapeuticsNew York · Post-IPO Equity
Asher BioSan Francisco · Series C
Enliven TherapeuticsBoulder · Series B
Flare TherapeuticsCambridge · Series B
Revolution MedicinesRedwood City · Series C
Centessa PharmaceuticalsCambridge · Series A
Avidity BiosciencesSan Diego · Post-IPO Equity
Vivace TherapeuticsSan Mateo · Series C
Palisade BioCarlsbad · Post-IPO Equity
Third Harmonic BioCambridge · Series B
ArvinasNew Haven · Post-IPO Equity
Nurix TherapeuticsSan Francisco · Private Equity
Red Arrow TherapeuticsMinato · Series A
Rain OncologyNewark · Series B
Fate TherapeuticsLa Jolla · Post-IPO Equity
Theseus PharmaceuticalsNew York · Series B
Akero TherapeuticsCambridge · Post-IPO Equity
CiVi BiopharmaChevy Chase · Venture
Passage BioPhiladelphia · Series B
Poseida TherapeuticsSan Diego · Series C
AtrecaSouth San Francisco · Series C
Point BiopharmaIndianapolis · Post-IPO Equity
Connect BiopharmaceuticalsTaicang · Series C
ITeos TherapeuticsCambridge · Post-IPO Equity
GTxMemphis · Post-IPO Equity
Portfolio map
2 Boxer Capital portfolio companies on the map.